Related Experiment Video

Updated: Jun 16, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Interleukin-29 binds to melanoma cells inducing Jak-STAT signal transduction and apoptosis

Kristan D Guenterberg1, Valerie P Grignol, Ene T Raig

  • 1Department of Surgery, Division of Surgical Oncology, The Ohio State University, Arthur G James Cancer Hospital and Richard J SoloveResearch Institute, Columbus, Ohio 43210, USA.

Molecular Cancer Therapeutics
|January 28, 2010
PubMed

Insights

Interleukin-29 (IL-29) receptors are present on melanoma cells and tumors. IL-29 treatment activates signaling pathways, increases gene expression, and induces apoptosis, offering potential therapeutic strategies for melanoma.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Interleukin-29 (IL-29) is a type III interferon with known antiviral and anti-proliferative properties.
  • Melanoma, a significant form of skin cancer, requires novel therapeutic targets.
  • Understanding the role of IL-29 in melanoma could reveal new treatment avenues.

Purpose of the Study:

  • To investigate the expression of the IL-29 receptor (IL-29R) on melanoma cell lines and patient samples.
  • To determine the functional response of melanoma cells to IL-29 treatment.
  • To explore the potential of IL-29 as a therapeutic agent in melanoma.

Main Methods:

  • Reverse transcription-PCR (RT-PCR) to assess IL-29 receptor component expression (IL-28R1, IL-10R2).
  • Immunoblot analysis and flow cytometry to study IL-29-induced signal transduction (STAT1, STAT2 phosphorylation).
  • Microarray analysis, real-time PCR, and Annexin V/propidium iodide staining to evaluate gene expression and apoptosis.
  • In situ PCR on melanoma tumors and benign nevi for IL-29R detection.

Main Results:

  • IL-28R1 and IL-10R2 were expressed on multiple human melanoma cell lines.
  • IL-29 treatment induced STAT1 and STAT2 phosphorylation, indicating activation of the Jak-STAT pathway.
  • IL-29 upregulated IFN-regulated genes and synergistically enhanced chemotherapy-induced apoptosis in a melanoma cell line.
  • IL-29 receptor components were detected in primary melanoma tumors but not in benign nevi.

Conclusions:

  • Human melanoma cells and tumors express functional IL-29 receptors.
  • IL-29 activates specific signaling pathways and gene transcription in melanoma cells.
  • IL-29 demonstrates potential as an adjuvant therapy to enhance apoptosis in melanoma treatment.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...